Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.47 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | GAA | P10253 | 6/20 | 0.47 |
| ▸ | GFER | P55789 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | NPY1R | P25929 | 1/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5027098 | 0.84 | MAPT (0.48) | MEN1KMT2AMAPTGAAGFER | |
| SCHEMBL5027100 | 0.84 | MAPT (0.48) | MEN1KMT2AMAPTGAAGFER | |
| SCHEMBL5442763 | 0.83 | MEN1 (0.47) | MEN1KMT2AMAPTGAAGFER | |
| SCHEMBL8357961 | 0.83 | MEN1 (0.47) | MEN1KMT2AMAPTGAAGFER | |
| SCHEMBL5442765 | 0.83 | MEN1 (0.47) | MEN1KMT2AMAPTGAAGFER | |
| SCHEMBL16379201 | 0.81 | MEN1 (0.56) | MEN1KMT2AMAPTGAAGFER | |
| SCHEMBL518727 | 0.81 | MEN1 (0.52) | MEN1KMT2AMAPTGAAGFER | |
| SCHEMBL15047078 | 0.80 | CA1 (0.52) | MEN1KMT2AMAPTGAAGFER | |
| SCHEMBL9068078 | 0.80 | CA1 (0.52) | MEN1KMT2AMAPTGAAGFER | |
| SCHEMBL9068333 | 0.80 | CA1 (0.52) | MEN1KMT2AMAPTGAAGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150004100-A1 | HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY | GE HEALTHCARE LIMITED (GB) | 2015-01-01 | — | — | US | disclosed |
| WO-2013090497-A1 | HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY | GE HEALTHCARE LIMITED (GB) | 2013-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150004100-A1 | HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY | MAPT, NAT1, APP | MEN1 3569/4885KMT2A 3931/4885MAPT 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.